InfuSystem is becoming a broader outpatient equipment services platform while deliberately shrinking an unattractive biomedical contract. Compression therapy offers a new growth channel, but the investment case rests on collecting profitable revenue rather than simply supplying more devices. Chief executive Carrie Lachance's emphasis on “pursuing profitable growth” captures the strategic change. The GE Healthcare contract reset has improved profitability by removing more expense than revenue. That strengthens the operating foundation without proving that every new therapy earns comparable returns.
The second quarter ended June 30, 2026 illustrates the tension. Patient Services revenue grew 15.2%, helped by oncology and newly introduced compression products. Its gross margin nevertheless declined because wound care carries a lower margin than the established oncology franchise. Meanwhile, the smaller Device Solutions business preserved gross profit despite its revenue decline. The resulting enterprise is more profitable, but its growth and margin improvements come from different sources. Neither development alone establishes a durable acceleration in cash available to shareholders.
At approximately 8.2 times trailing adjusted earnings before interest, taxes, depreciation and amortization, the enterprise valuation recognizes an established service franchise rather than an undiscovered turnaround. First-half free cash flow before equipment disposal proceeds was only $1.0 million, constraining the immediate cash support for repurchases. Management reaffirmed its annual outlook rather than raising it after the stronger quarter. Can compression distribution and the newly installed business systems convert the platform's access to patients and payers into repeatable cash growth as the contract-reset comparison fades?